SCHEMBL25950809

SCHEMBL25950809

Cc1cc(CO)c(Cl)c(C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.52
CYP2C9 P11712 5/20 0.50
CYP2C19 P33261 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HIF1A Q16665 4/20 0.50
ALDH1A1 P00352 3/20 0.47
CA2 P00918 2/20 0.47
POLB P06746 1/20 0.47
TYR P14679 1/20 0.47
CYP2D6 P10635 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TP53 P04637 2/20 0.36
CYP1A2 P05177 3/20 0.32
ALOX15 P16050 2/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPT P10636 1/20 0.32
ATP2A2 P16615 1/20 0.32
ATP2A3 Q93084 1/20 0.32
KLF10 Q13118 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104527 0.83 HSPA5 (0.42) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL25449368 0.82 PDK2 (0.37) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL21514051 0.82 HSPA5 (0.48) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL31519169 0.79 ALDH1A1 (0.56) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL10245551 0.78 HSPA5 (0.75) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL11270964 0.75 CYP3A4 (0.41) ALDH1A1POLBALOX15KDM4EMAPT
SCHEMBL10611171 0.74 HSPA5 (0.47) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL20457051 0.73 SMN1; SMN2 (0.50) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL18050603 0.73 SMN1; SMN2 (0.56) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL14217009 0.72 HSPA5 (0.46) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B HSPA5 682/4885CYP2C9 758/4885CYP2C19 367/4885
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B HSPA5 682/4885CYP2C9 758/4885CYP2C19 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.